Chinese cancer therapy developer BeiGene Ltd. is planning an IPO of its shares in Hong Kong.
The biopharmaceutical company, which was founded in 2010 and employs 900 individuals, will offer about 5,904,000 shares on the main board of The Stock Exchange of Hong Kong Ltd, or SEHK.
The Nasdaq-listed company will be taking advantage of rule changes at the Hong Kong Exchanges & Clearing Ltd., the parent of SEHK, which encourage biotech companies that are not yet generating revenue or profit to list in Hong Kong.
According to S&P Capital IQ, the company has not posted a profit in at least the past five years.
Concurrent to the Hong Kong IPO, BeiGene will also offer about 59,696,000 shares in a global offering of securities.
The offerings will be priced at a later date and will see Morgan Stanley & Co. International PLC, Goldman Sachs (Asia) LLC, Credit Suisse (Hong Kong) Ltd. and CLSA Ltd. acting as joint global coordinators.
The coordinators can buy up to an additional 9,840,000 shares from the company which last raised about $800 million from an offering of 7,920,800 American depositary shares on the Nasdaq Global Select Market under the symbol BGNE.
Each ADS was priced at $101 per share and represented 13 ordinary shares of the company.
BeiGene's product portfolio includes multiple assets in various stages of development for the treatment of different cancer types. The immuno-oncology medicines work by enabling a patient's immune system to fight cancer.